Credit Suisse Ag Aim Immuno Tech Inc. Transaction History
Credit Suisse Ag
- $101 Billion
- Q1 2024
Shares
3 transactions
Others Institutions Holding AIM
# of Institutions
36Shares Held
9.01MCall Options Held
0Put Options Held
0-
Armistice Capital, LLC New York, NY4.33MShares$909,3000.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.99MShares$417,6270.0% of portfolio
-
Black Rock Inc. New York, NY698KShares$146,6360.0% of portfolio
-
Geode Capital Management, LLC Boston, MA464KShares$97,4430.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il458KShares$96,1310.0% of portfolio
About AIM ImmunoTech Inc.
- Ticker AIM
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,049,300
- Market Cap $10.1M
- Description
- AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome...